Patents Assigned to Hikma Pharmaceuticals
-
Patent number: 10722510Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention both intranasally and sublingually to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally and sublingually the naloxone formulations of the present invention.Type: GrantFiled: August 17, 2016Date of Patent: July 28, 2020Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Kiran Amancha, Shivani Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Patent number: 10617637Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: GrantFiled: June 29, 2018Date of Patent: April 14, 2020Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Patent number: 10617686Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: GrantFiled: May 22, 2017Date of Patent: April 14, 2020Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Kiran Amancha, Shivani Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda, Eshwaran Narayanan
-
Patent number: 10441538Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: GrantFiled: January 22, 2018Date of Patent: October 15, 2019Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda, Eshwaran Narayanan
-
Patent number: 10357621Abstract: A connector mountable to a syringe barrel has a proximal barrel-engaging portion, a distal luer fitment portion, and a fluid aperture therethrough. The barrel-engaging portion of the connector includes an axial ledge configured to abut the axial distal edge of a glass syringe barrel. The connector facilitates mounting a luer assembly to the barrel. The luer assembly may be a tip cap having a complementary luer fitment for connection to the luer fitment portion of the connector. The luer assembly may be a luer needle assembly having a complementary luer fitment for connection to the luer fitment portion of the connector. The connector and syringe may further include an immobile, compressible needle seal. The needle seal is adjacent to or engageable with the barrel-engaging portion of the connector. The syringe may be configured with a plunger capable of engaging a retractable needle.Type: GrantFiled: November 17, 2016Date of Patent: July 23, 2019Assignee: Hikma Pharmaceuticals LLCInventors: Jyoti Gupta, Brandon J. McKee, Daniel A. Heinsbergen
-
Patent number: 9789108Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.Type: GrantFiled: December 10, 2014Date of Patent: October 17, 2017Assignee: Hikma Pharmaceuticals LLCInventor: Murray Ducharme
-
Patent number: 9675613Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.Type: GrantFiled: October 10, 2014Date of Patent: June 13, 2017Assignee: Hikma Pharmaceuticals LLCInventor: Murray Ducharme
-
Patent number: 9555029Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.Type: GrantFiled: December 11, 2014Date of Patent: January 31, 2017Assignee: HIKMA PHARMACEUTICALS LLCInventor: Murray Ducharme
-
Patent number: 9399036Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.Type: GrantFiled: December 10, 2014Date of Patent: July 26, 2016Assignee: Hikma Pharmaceuticals LLCInventor: Murray Ducharme
-
Patent number: 9211335Abstract: The present invention relates to stabilized pharmaceutical formulations prepared from solutions comprising an antineoplastic compound having a cyclic or non-cyclic hydrazine, triazine, or tetrazine group, or a pharmaceutically acceptable salt thereof, and a stabilizer, wherein the stabilizer is an antioxidant and/or more susceptible to nucleophilic attack than the antineoplastic compound.Type: GrantFiled: June 25, 2014Date of Patent: December 15, 2015Assignee: Hikma PharmaceuticalsInventors: Mahmoud S. AlSwisi, Mahmoud A. A. Ghannam
-
Patent number: 9211336Abstract: The present invention relates to stabilized pharmaceutical formulations prepared from solutions comprising an antineoplastic compound having a cyclic or non-cyclic hydrazine, triazine, or tetrazine group, or a pharmaceutically acceptable salt thereof, and a stabilizer, wherein the stabilizer is an antioxidant and/or more susceptible to nucleophilic attack than the antineoplastic compound.Type: GrantFiled: February 3, 2015Date of Patent: December 15, 2015Assignee: HIKMA PHARMACEUTICALSInventors: Mahmoud S. AlSwisi, Mahmoud A. A. Ghannam
-
Publication number: 20150094317Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.Type: ApplicationFiled: December 10, 2014Publication date: April 2, 2015Applicant: Hikma Pharmaceuticals LLCInventor: Murray DUCHARME
-
Publication number: 20150094318Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.Type: ApplicationFiled: December 10, 2014Publication date: April 2, 2015Applicant: HIKMA PHARMACEUTICALS LLCInventor: Murray Ducharme
-
Publication number: 20150094375Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.Type: ApplicationFiled: December 11, 2014Publication date: April 2, 2015Applicant: Hikma Pharmaceuticals LLCInventor: Murray Ducharme
-
Patent number: 8974811Abstract: The present invention relates to stabilized pharmaceutical formulations prepared from solutions comprising an antineoplastic compound having a cyclic or non-cyclic hydrazine, triazine, or tetrazine group, or a pharmaceutically acceptable salt thereof, and a stabilizer, wherein the stabilizer is an antioxidant and/or more susceptible to nucleophilic attack than the antineoplastic compound.Type: GrantFiled: March 14, 2013Date of Patent: March 10, 2015Assignee: Hikma PharmaceuticalsInventors: Mahmoud S. AlSwisi, Mahmoud A. A. Ghannam
-
Publication number: 20150057359Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.Type: ApplicationFiled: October 10, 2014Publication date: February 26, 2015Applicant: HIKMA PHARMACEUTICALS LLCInventor: Murray Ducharme
-
Patent number: 8927607Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.Type: GrantFiled: August 22, 2013Date of Patent: January 6, 2015Assignee: Hikma Pharmaceuticals LLCInventor: Murray Ducharme
-
Patent number: 8173169Abstract: The present invention provides pharmaceutical tablets comprising modafinil particles, processes for preparing such pharmaceutical tablets, and methods of treating a disease or disorder using the pharmaceutical tablet of the invention. In particular, the pharmaceutical tablet of the invention comprises modafinil particles and one or more pharmaceutically acceptable excipients, wherein the modafinil particles have a size distribution such that at least about 65% of the modafinil particles have a diameter greater than 220 microns and the tablet is bioequivalent to PROVIGIL®. The pharmaceutical tablet of the invention is prepared by a dry granulation method.Type: GrantFiled: July 11, 2007Date of Patent: May 8, 2012Assignee: Hikma PharmaceuticalsInventors: Mohannad Shawer, AlSayed AlArabi Sallam, Dalia Jawhari
-
Publication number: 20070275057Abstract: The present invention provides pharmaceutical tablets comprising modafinil particles, processes for preparing such pharmaceutical tablets, and methods of treating a disease or disorder using the pharmaceutical tablet of the invention. In particular, the pharmaceutical tablet of the invention comprises modafinil particles and one or more pharmaceutically acceptable excipients, wherein the modafinil particles have a size distribution such that at least about 65% of the modafinil particles have a diameter greater than 220 microns and the tablet is bioequivalent to PROVIGIL®. The pharmaceutical tablet of the invention is prepared by a dry granulation method.Type: ApplicationFiled: July 11, 2007Publication date: November 29, 2007Applicant: HIKMA PHARMACEUTICALSInventors: Mohannad Shawer, AlSayed Sallam, Dalia Jawhari
-
Publication number: 20070043003Abstract: Novel compounds are disclosed for the prophylaxis and treatment of inflammatory bowel disease (IBD) via the administration of an effective amount in a suitable pharmaceutical dosage of agents that are active by themselves or can deliver tin the large intestine active forms of the drugs such as 5ASA or benzoxazole acetic acid or platelet activating factors. The mechanism of the release is based on bacterial cleavage of an azo linkage in the mammalian lower bowel to release the active compound(s).Type: ApplicationFiled: January 30, 2006Publication date: February 22, 2007Applicant: Hikma Pharmaceuticals Co., Ltd.Inventor: Jamal Jilani